0000000000590474

AUTHOR

Verónica Vidal

showing 4 related works from this author

Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study

2019

Patients with established cardiovascular disease may suffer further cardiovascular events, despite receiving optimal medical treatment. Although platelet inhibition plays a central role in the prevention of new events, the use of anticoagulant therapies to reduce events in atheromatous disease has, until recently, been overlooked. The recent Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS) study showed an important reduction in cardiovascular events without increasing the risk of fatal and intracranial bleeding when using rivaroxaban, a novel oral anticoagulant, combined with aspirin. This article reviews the available evidence…

Rivaroxabanmedicine.medical_specialtyAspirinmedicine.drug_classbusiness.industryArterial diseaseAnticoagulantDisease030204 cardiovascular system & hematologymedicine.diseaseThrombosisPharmacotherapyPeripheralClinical Practice03 medical and health sciences0302 clinical medicinemedicine030212 general & internal medicineCardiology and Cardiovascular MedicineIntensive care medicinebusinessmedicine.drugEuropean Cardiology Review
researchProduct

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron : The Myocardial- Trial

2020

Background Intravenous ferric carboxymaltose ( FCM ) improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The aim of this study was to examine changes in myocardial iron content after FCM administration in patients with heart failure and iron deficiency using cardiac magnetic resonance. Methods and Results Fifty‐three stable heart failure and iron deficiency patients were randomly assigned 1:1 to receive intravenous FCM or placebo in a multicenter, double‐blind study. T2* and T1 mapping cardiac magnetic resonance sequences, noninvasive surrogates of intramyocardial iron, were eval…

MaleCardiac magnetic resonance*ferric carboxymaltoseMagnetic Resonance Imaging (MRI)Myocardial ironAnèmia*heart failure030204 cardiovascular system & hematologyFerric Compounds0302 clinical medicine030212 general & internal medicineOriginal Researchcardiac magnetic resonance ferric carboxymaltose heart failure iron deficiency myocardial ironAnemia Iron-DeficiencyAnemiaIron deficiencyMiddle AgedMyocardial ironMagnetic Resonance Imaging*myocardial ironMagnetic resonanceCardiologyAdministration IntravenousFemaleCardiology and Cardiovascular Medicine*cardiac magnetic resonancemedicine.medical_specialtyNoninvasive imagingCardiomyopathyIronIntravenous ironHeart failureFERRIC CARBOXYMALTOSE03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMaltoseAgedPharmacologybusiness.industryMyocardiumIron deficiencyRessonància magnèticaMiocardimedicine.diseaseFerric carboxymaltoseTreatmentHeart failureHematinicsbusinessCardiac magnetic resonance*iron deficiencyFerro
researchProduct

Characterization and implications of the dynamics of eosinophils in blood and in the infarcted myocardium after coronary reperfusion.

2018

Objective We characterized the dynamics of eosinophils in blood and in the infarcted myocardium in patients and in a swine model of reperfused myocardial infarction (MI). The association of eosinophil dynamics with various outcomes was assessed. Methods Serial eosinophil count and pre-discharge cardiac magnetic resonance were carried out in a prospective series of 620 patients with a first ST-elevation MI. In a swine model of reperfused MI, the dynamics of circulating eosinophils and their presence in the infarcted myocardium were determined. In autopsies from chronic MI patients, eosinophils were quantified. Results Patient eosinophil count sharply decreased 12h post-reperfusion compared t…

0301 basic medicineMaleCritical Care and Emergency MedicineSwinePhysiologyMyocardial Infarctionlcsh:MedicineCell Count030204 cardiovascular system & hematologyPathology and Laboratory MedicineVascular MedicineWhite Blood Cells0302 clinical medicineEosinophil migrationAnimal CellsIschemiaEdemaMedicine and Health SciencesEosinopeniaEdemaMyocardial infarctionlcsh:ScienceEosinophil cationic proteinMultidisciplinaryHeartMiddle AgedBody Fluidsmedicine.anatomical_structureBloodCardiologycardiovascular systemCytokinesFemalemedicine.symptomCellular TypesAnatomyResearch Articlemedicine.medical_specialtyImmune CellsImmunologyIschemiaCardiologyMyocardial Reperfusion03 medical and health sciencesSigns and SymptomsDiagnostic MedicineInternal medicinemedicineAnimalsHumanscardiovascular diseasesBlood Cellsbusiness.industryMyocardiumlcsh:RBiology and Life SciencesCell BiologyEosinophilmedicine.diseaseEosinophilsBlood Counts030104 developmental biologyHeart failureReperfusionCardiovascular Anatomylcsh:QbusinessPloS one
researchProduct

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

2020

Abstract Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal funct…

medicine.medical_specialtyUrologyRenal function030204 cardiovascular system & hematologySacubitril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHeart failure with reduced ejection fraction (HFrEF)Original Research ArticlesRenal safety profileType 2 diabetes mellitusEmpagliflozinDiseases of the circulatory (Cardiovascular) systemMedicineSGLT2iOriginal Research Article030212 general & internal medicineSacubitril/valsartanCreatinineEjection fractionbusiness.industrymedicine.diseasechemistryValsartanRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drugRenal function
researchProduct